The Food and Drug Administration yesterday authorized for emergency use a new drug to treat hospitalized patients receiving systemic corticosteroids who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation. Actemra (tocilizumab) reduced the risk of death, ventilator use and time in the hospital for patients who received the drug in clinical trials. 

“Although vaccines have been successful in decreasing the number of patients with COVID-19 who require hospitalization, providing additional therapies for those who do become hospitalized is an important step in combating this pandemic,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research.

In other news, FDA is accepting comments through Aug. 24 on draft guidance encouraging clinical trials for cancer therapies to expand eligibility to patients with incurable cancers who have not previously received existing treatment options for their cancer. 
 

Related News Articles

Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…